395 related articles for article (PubMed ID: 27924064)
21. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
Bowles DW; McDermott JD; Jimeno A
Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
[TBL] [Abstract][Full Text] [Related]
22. Combination antiangiogenic therapy and radiation in head and neck cancers.
Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
[TBL] [Abstract][Full Text] [Related]
23. Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways.
Bancroft CC; Chen Z; Dong G; Sunwoo JB; Yeh N; Park C; Van Waes C
Clin Cancer Res; 2001 Feb; 7(2):435-42. PubMed ID: 11234901
[TBL] [Abstract][Full Text] [Related]
24. p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.
Wu D; Cheng J; Sun G; Wu S; Li M; Gao Z; Zhai S; Li P; Su D; Wang X
Oncotarget; 2016 Jun; 7(24):36539-36550. PubMed ID: 27174914
[TBL] [Abstract][Full Text] [Related]
25. The PI3K/Akt/mTOR axis in head and neck cancer: functions, aberrations, cross-talk, and therapies.
Vander Broek R; Mohan S; Eytan DF; Chen Z; Van Waes C
Oral Dis; 2015 Oct; 21(7):815-25. PubMed ID: 24219320
[TBL] [Abstract][Full Text] [Related]
26. To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer.
Lee RH; Johnson DE; Grandis JR
Cancer Res; 2023 Oct; 83(19):3162-3164. PubMed ID: 37779427
[TBL] [Abstract][Full Text] [Related]
27. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
28. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
Xie J; Li Q; Ding X; Gao Y
Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
[TBL] [Abstract][Full Text] [Related]
29. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
[TBL] [Abstract][Full Text] [Related]
30. SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.
Barzegar M; Ma S; Zhang C; Chen X; Gu Y; Shang C; Jiang X; Yang J; Nathan CA; Yang S; Huang S
Br J Cancer; 2017 Oct; 117(8):1154-1163. PubMed ID: 28873083
[TBL] [Abstract][Full Text] [Related]
31. New promising molecular targets in head and neck squamous cell carcinoma.
Bauman JE; Michel LS; Chung CH
Curr Opin Oncol; 2012 May; 24(3):235-42. PubMed ID: 22327839
[TBL] [Abstract][Full Text] [Related]
32. Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications.
Perri F; Pacelli R; Della Vittoria Scarpati G; Cella L; Giuliano M; Caponigro F; Pepe S
Head Neck; 2015 May; 37(5):763-70. PubMed ID: 24995469
[TBL] [Abstract][Full Text] [Related]
33. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
34. Precision Therapy of Head and Neck Squamous Cell Carcinoma.
Polverini PJ; D'Silva NJ; Lei YL
J Dent Res; 2018 Jun; 97(6):614-621. PubMed ID: 29649374
[TBL] [Abstract][Full Text] [Related]
35. Predictive Value of EGFR-PI3K-AKT-mTOR-Pathway Inhibitor Biomarkers for Head and Neck Squamous Cell Carcinoma: A Systematic Review.
de Kort WWB; Spelier S; Devriese LA; van Es RJJ; Willems SM
Mol Diagn Ther; 2021 Mar; 25(2):123-136. PubMed ID: 33686517
[TBL] [Abstract][Full Text] [Related]
36. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling.
Daly C; Castanaro C; Zhang W; Zhang Q; Wei Y; Ni M; Young TM; Zhang L; Burova E; Thurston G
Oncogene; 2017 Jan; 36(4):471-481. PubMed ID: 27345413
[TBL] [Abstract][Full Text] [Related]
37. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
[TBL] [Abstract][Full Text] [Related]
38. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
39. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01.
Amornphimoltham P; Sriuranpong V; Patel V; Benavides F; Conti CJ; Sauk J; Sausville EA; Molinolo AA; Gutkind JS
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4029-37. PubMed ID: 15217935
[TBL] [Abstract][Full Text] [Related]
40. RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.
Tumur Z; Katebzadeh S; Guerra C; Bhushan L; Alkam T; Henson BS
Neoplasia; 2015 Jan; 17(1):141-51. PubMed ID: 25622907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
